ProCE Banner Activity

A Phase II Trial of Venetoclax, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
VenKd was well tolerated with promising response rates in R/R MM, including both high-risk and standard-risk patients, in a phase II trial.

Released: June 04, 2018

Expiration: June 03, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen